معرفی
Dr. Victoria Ozberk is a Research Fellow at Griffith University's Institute for Biomedicine and Glycomics. Her work focuses on vaccine development against infectious diseases, particularly Group A Streptococcus (Strep A). She has contributed to a Phase 1 clinical trial of a Strep A vaccine, demonstrating safety and immunogenicity. Her research integrates immunology, microbiology, and nanotechnology to design novel vaccine delivery systems, including liposomal and poly(amino acid)-based platforms. Dr. Ozberk's team has secured grants from the Leducq Foundation and Griffith University to advance Strep A vaccine efficacy trials and immunotherapy for rheumatic heart disease.
Her research interests include mucosal immunity, immune evasion mechanisms, and the development of temperature-stable vaccines. Notable projects include studies on IL-17-mediated protection against streptococcal infections and the use of combinatorial vaccines to combat co-infections. Dr. Ozberk serves as an Associate Supervisor for a doctoral project on futureproofing COVID-19 vaccines through combinatorial B- and T-cell epitope approaches.
- Education: PhD in Biomedical Sciences (Griffith University, 2018)
- Key Grants:
- Leducq Foundation Grant (2023–2025): $5M for Strep A vaccine clinical development
- Griffith University Internal Grant (2022–2025): $410K for Streptococcal toxic shock immunotherapy
- Impact: Collaborates with global institutions to advance vaccines targeting Strep A, aiming to reduce rheumatic heart disease prevalence in vulnerable populations.
Dr. Ozberk's lab is part of the Griffith Institute for Biomedicine and Glycomics, emphasizing translational research in infectious disease prevention and treatment.
